Skip to main content
Top
Published in: Journal of Neural Transmission 3/2021

Open Access 01-03-2021 | Dystonia | Neurology and Preclinical Neurological Studies - Original Article

Botulinum toxin dosing in arm muscles: contextual factors

Authors: Dirk Dressler, Bruno Kopp, Fereshte Adib Saberi

Published in: Journal of Neural Transmission | Issue 3/2021

Login to get access

Abstract

Botulinum toxin (BT) has been successfully used for many years to treat various muscle hyperactivity disorders including dystonia and spasticity. Its dosing is guided by dosing tables describing target muscles and dose ranges. To refine the BT dosing, we wanted to analyse how contextual factors may influence the injector's final dosing decision.
In a retrospective review of real-life data of 1170 BT treatments, we studied the influence of various contextual factors on the BT doses in 21 arm muscles of 252 patients receiving BT therapy for different muscle hyperactivity disorders.
We found that BT arm doses are significantly higher in treatment of spasticity than in treatment of dystonia. We also found that spontaneous arm dystonia requires higher BT doses in a proximal application pattern, whereas task specific writer's cramp requires considerably reduced BT doses with a distal application pattern. Injections of non-arm muscles influence the BT dosing in arm muscles only marginally.
Our study demonstrates that BT dosing does not only depend on the particularities of the individual target muscle injected, such as its volume and its static or phasic function. BT dosing and its application pattern rather depend on additional contextual factors such as the aetiology and pathophysiology of the muscle hyperactivity treated. These contextual factors need to be included in dosing tables and may improve the outcome of BT therapy.
Literature
go back to reference Dressler D (2000) Botulinum Toxin Therapy. Thieme, Stuttgart Dressler D (2000) Botulinum Toxin Therapy. Thieme, Stuttgart
go back to reference Dressler D (2009) Routine use of Xeomin® in patients pre-treated with Botox®. Eur J Neurol 16(Suppl 2):2–5CrossRef Dressler D (2009) Routine use of Xeomin® in patients pre-treated with Botox®. Eur J Neurol 16(Suppl 2):2–5CrossRef
go back to reference Dressler D (2010) Comparing Botox® and Xeomin® for the treatment of axillar hyperhidrosis. J Neural Transm 117:317–319CrossRef Dressler D (2010) Comparing Botox® and Xeomin® for the treatment of axillar hyperhidrosis. J Neural Transm 117:317–319CrossRef
go back to reference Dressler D (2018) Dosing Schemes for Botulinum Toxin Therapy of Dystonia. In: Dressler D, Altenmüller E, Krauss JK (eds) Treatment of Dystonia. Cambridge University Press, CambridgeCrossRef Dressler D (2018) Dosing Schemes for Botulinum Toxin Therapy of Dystonia. In: Dressler D, Altenmüller E, Krauss JK (eds) Treatment of Dystonia. Cambridge University Press, CambridgeCrossRef
go back to reference Dressler D, Mander G, Fink K (2012) Measuring the potency labelling of onabotulinumtoxinA (Botox®) and Xeomin® in an LD50 assay. J Neural Transm 119:13–15CrossRef Dressler D, Mander G, Fink K (2012) Measuring the potency labelling of onabotulinumtoxinA (Botox®) and Xeomin® in an LD50 assay. J Neural Transm 119:13–15CrossRef
go back to reference Dressler D, Adib Saberi F, Kollewe K, Schrader C (2014a) Safety aspects of incobotulinumtoxinA high dose therapy. J Neural Transm 122:327–333CrossRef Dressler D, Adib Saberi F, Kollewe K, Schrader C (2014a) Safety aspects of incobotulinumtoxinA high dose therapy. J Neural Transm 122:327–333CrossRef
go back to reference Dressler D, Tacik P, Adib Saberi F (2014b) Botulinum toxin therapy of cervical dystonia: Comparing Botox® and Xeomin®. J Neural Transm 121:29–31CrossRef Dressler D, Tacik P, Adib Saberi F (2014b) Botulinum toxin therapy of cervical dystonia: Comparing Botox® and Xeomin®. J Neural Transm 121:29–31CrossRef
go back to reference Dressler D, Bhidayasiri R, Bohlega S, Chahidi A, Mo Chung T, Ebke M, Jacinto LJ, Kaji R, Koçer S, Kanovsky P, Micheli F, Orlova O, Paus S, Pirtosek Z, Relja M, Rosales RL, Sagástegui-Rodríguez JA, Schoenle PW, Shahidi GA, Timerbaeva S, Walter U, Adib Saberi F (2017) Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB - interdisciplinary working group for movement disorders task force. J Neurol 264:112–120CrossRef Dressler D, Bhidayasiri R, Bohlega S, Chahidi A, Mo Chung T, Ebke M, Jacinto LJ, Kaji R, Koçer S, Kanovsky P, Micheli F, Orlova O, Paus S, Pirtosek Z, Relja M, Rosales RL, Sagástegui-Rodríguez JA, Schoenle PW, Shahidi GA, Timerbaeva S, Walter U, Adib Saberi F (2017) Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB - interdisciplinary working group for movement disorders task force. J Neurol 264:112–120CrossRef
go back to reference Dressler D, Pan L, Bigalke H (2018) Comparing IncobotulinumtoxinA (Xeomin®) and OnabotulinumtoxinA (Botox®): Identical Potency Labelling in the Hemidiaphragm Assay. J Neural Transm 125:1351–1354CrossRef Dressler D, Pan L, Bigalke H (2018) Comparing IncobotulinumtoxinA (Xeomin®) and OnabotulinumtoxinA (Botox®): Identical Potency Labelling in the Hemidiaphragm Assay. J Neural Transm 125:1351–1354CrossRef
go back to reference Wissel J, Bensmail D, Ferreira J, Molteni F, Satkunam L, Moraleda S, Rekand T, McGuire J, Scheschonka A, Flatau-Baqué B, Simon O, Dressler D, Simpson DM (2017) Safety and efficacy of incobotulinumtoxinA doses up to 800 U in spasticity: the TOWER study. Neurology 88:1321–1328CrossRef Wissel J, Bensmail D, Ferreira J, Molteni F, Satkunam L, Moraleda S, Rekand T, McGuire J, Scheschonka A, Flatau-Baqué B, Simon O, Dressler D, Simpson DM (2017) Safety and efficacy of incobotulinumtoxinA doses up to 800 U in spasticity: the TOWER study. Neurology 88:1321–1328CrossRef
Metadata
Title
Botulinum toxin dosing in arm muscles: contextual factors
Authors
Dirk Dressler
Bruno Kopp
Fereshte Adib Saberi
Publication date
01-03-2021
Publisher
Springer Vienna
Published in
Journal of Neural Transmission / Issue 3/2021
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-021-02307-1

Other articles of this Issue 3/2021

Journal of Neural Transmission 3/2021 Go to the issue

Neurology and Preclinical Neurological Studies - Review Article

Neuronal intranuclear inclusion disease: recognition and update

Neurology and Preclinical Neurological Studies - Review Article

Emergent creativity in frontotemporal dementia